BACKGROUND: The molecular factors that control parathyroid tumorigenesis are poorly understood. In the absence of local invasion or metastasis, distinguishing benign from malignant parathyroid neoplasm is difficult on histologic examination. We studied the microRNA (miRNA) profile in normal, hyperplastic, and benign and malignant parathyroid tumors to better understand the molecular factors that may play a role in parathyroid tumorigenesis and that may serve as diagnostic markers for parathyroid carcinoma. METHODS: miRNA arrays containing 825 human microRNAs with four duplicate probes per miRNA were used to profile parathyroid tumor (12 adenomas, 9 carcinomas, and 15 hyperplastic) samples normalized to four reference normal parathyroid glands. Differentially expressed miRNA were validated by real-time quantitative TaqMan polymerase chain reaction (PCR). RESULTS: One hundred fifty-six miRNAs in parathyroid hyperplasia, 277 microRNAs in parathyroid adenoma, and 167 microRNAs in parathyroid carcinomas were significantly dysregulated as compared with normal parathyroid glands [false discovery rate (FDR) < 0.05]. By supervised clustering analysis, all parathyroid carcinomas clustered together. Three miRNAs (miR-26b, miR-30b, and miR-126*) were significantly dysregulated between parathyroid carcinoma and parathyroid adenoma. Receiver-operating characteristic curve analysis showed mir-126* was the best diagnostic marker, with area under the curve of 0.776. CONCLUSIONS: Most miRNAs are downregulated in parathyroid carcinoma, while in parathyroid hyperplasia most miRNAs are upregulated. miRNA profiling shows distinct differentially expressed miRNAs by tumor type which may serve as helpful adjunct to distinguish parathyroid adenoma from carcinoma.
BACKGROUND: The molecular factors that control parathyroid tumorigenesis are poorly understood. In the absence of local invasion or metastasis, distinguishing benign from malignant parathyroid neoplasm is difficult on histologic examination. We studied the microRNA (miRNA) profile in normal, hyperplastic, and benign and malignant parathyroid tumors to better understand the molecular factors that may play a role in parathyroid tumorigenesis and that may serve as diagnostic markers for parathyroid carcinoma. METHODS: miRNA arrays containing 825 human microRNAs with four duplicate probes per miRNA were used to profile parathyroid tumor (12 adenomas, 9 carcinomas, and 15 hyperplastic) samples normalized to four reference normal parathyroid glands. Differentially expressed miRNA were validated by real-time quantitative TaqMan polymerase chain reaction (PCR). RESULTS: One hundred fifty-six miRNAs in parathyroid hyperplasia, 277 microRNAs in parathyroid adenoma, and 167 microRNAs in parathyroid carcinomas were significantly dysregulated as compared with normal parathyroid glands [false discovery rate (FDR) < 0.05]. By supervised clustering analysis, all parathyroid carcinomas clustered together. Three miRNAs (miR-26b, miR-30b, and miR-126*) were significantly dysregulated between parathyroid carcinoma and parathyroid adenoma. Receiver-operating characteristic curve analysis showed mir-126* was the best diagnostic marker, with area under the curve of 0.776. CONCLUSIONS: Most miRNAs are downregulated in parathyroid carcinoma, while in parathyroid hyperplasia most miRNAs are upregulated. miRNA profiling shows distinct differentially expressed miRNAs by tumor type which may serve as helpful adjunct to distinguish parathyroid adenoma from carcinoma.
Authors: J D Carpten; C M Robbins; A Villablanca; L Forsberg; S Presciuttini; J Bailey-Wilson; W F Simonds; E M Gillanders; A M Kennedy; J D Chen; S K Agarwal; R Sood; M P Jones; T Y Moses; C Haven; D Petillo; P D Leotlela; B Harding; D Cameron; A A Pannett; A Höög; H Heath; L A James-Newton; B Robinson; R J Zarbo; B M Cavaco; W Wassif; N D Perrier; I B Rosen; U Kristoffersson; P D Turnpenny; L-O Farnebo; G M Besser; C E Jackson; H Morreau; J M Trent; R V Thakker; S J Marx; B T Teh; C Larsson; M R Hobbs Journal: Nat Genet Date: 2002-11-18 Impact factor: 38.330
Authors: Carola J Haven; Viive M Howell; Paul H C Eilers; Robert Dunne; Masayuki Takahashi; Marjo van Puijenbroek; Kyle Furge; Job Kievit; Min-Han Tan; Gert Jan Fleuren; Bruce G Robinson; Leigh W Delbridge; Jeanette Philips; Anne E Nelson; Ulf Krause; Henning Dralle; Cuong Hoang-Vu; Oliver Gimm; Hans Morreau; Deborah J Marsh; Bin T Teh Journal: Cancer Res Date: 2004-10-15 Impact factor: 12.701
Authors: Mohamed Guled; Leo Lahti; Pamela M Lindholm; Kaisa Salmenkivi; Izhar Bagwan; Andrew G Nicholson; Sakari Knuutila Journal: Genes Chromosomes Cancer Date: 2009-07 Impact factor: 5.006
Authors: Gustavo G Fernandez-Ranvier; Elham Khanafshar; David Tacha; Mariwil Wong; Electron Kebebew; Quan-Yang Duh; Orlo H Clark Journal: Cancer Date: 2009-01-15 Impact factor: 6.860
Authors: F Jardin; M Callanan; D Penther; P Ruminy; X Troussard; J P Kerckaert; M Figeac; F Parmentier; V Rainville; I Vaida; P Bertrand; A B Duval; J M Picquenot; L Chaperot; J P Marolleau; J Plumas; H Tilly; C Bastard Journal: Leukemia Date: 2009-01-22 Impact factor: 11.528
Authors: G Xu; C Ji; G Song; C Zhao; C Shi; L Song; L Chen; L Yang; F Huang; L Pang; N Zhang; Y Zhao; X Guo Journal: Int J Obes (Lond) Date: 2015-05-22 Impact factor: 5.095
Authors: Maria Mizamtsidi; Konstantinos Nastos; Fausto Palazzo; Vasilis Constantinides; Roberto Dina; Megan Farenden; George Mastorakos; Ioannis Vassiliou; Maria Gazouli Journal: In Vivo Date: 2019 Jul-Aug Impact factor: 2.155